HC Wainwright Lifts Earnings Estimates for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Equities researchers at HC Wainwright lifted their FY2029 earnings per share estimates for shares of Pyxis Oncology in a report released on Tuesday, March 24th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.27 per share for the year, up from their previous forecast of $0.21. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The firm had revenue of $11.04 million during the quarter, compared to the consensus estimate of $0.13 million.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Royal Bank Of Canada lowered their price objective on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus reduced their target price on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock opened at $1.39 on Wednesday. The stock has a market capitalization of $87.33 million, a PE ratio of -1.08 and a beta of 1.45. Pyxis Oncology has a 52-week low of $0.83 and a 52-week high of $5.55. The company has a 50-day simple moving average of $1.50 and a two-hundred day simple moving average of $2.50.

Institutional Trading of Pyxis Oncology

A number of large investors have recently made changes to their positions in PYXS. Bank of America Corp DE raised its holdings in shares of Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after purchasing an additional 9,062 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Pyxis Oncology in the first quarter worth approximately $81,000. XTX Topco Ltd bought a new stake in Pyxis Oncology in the 2nd quarter worth approximately $40,000. Marshall Wace LLP bought a new stake in Pyxis Oncology in the 2nd quarter worth approximately $163,000. Finally, Qube Research & Technologies Ltd raised its stake in Pyxis Oncology by 128.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock valued at $113,000 after buying an additional 57,935 shares during the last quarter. 39.09% of the stock is currently owned by institutional investors.

Key Stories Impacting Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and lifted several EPS estimates (FY2026→-0.95 from -1.28; FY2027→-0.85; FY2028→-0.34; FY2029→0.27; FY2030→0.83) while keeping a $7 price target — a clear bullish signal for future earnings trajectory. Read More.
• Positive Sentiment: Recent quarter: Pyxis reported a beat on the March quarter EPS (-$0.29 vs. -$0.35 consensus) and $11.0M revenue, which supports the analyst upgrades and contributed to improved sentiment. Read More.
• Neutral Sentiment: Analyst coverage remains mixed overall — consensus is still a “Moderate Buy” with an average $7.00 target, but ratings and targets vary across shops (five Buys, one Hold, one Sell), so conviction is not uniform. Read More.
• Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed multiple sales (most recently 13,896 shares at about $1.03). Insider exits can weigh on sentiment even if done for liquidity reasons; SEC Form 4 is filed. Read More. — SEC filing: Read More.
• Negative Sentiment: Some shops trimmed upside: Stifel reduced its price target (reported recently) which could temper momentum from HC Wainwright’s bullish note. Read More.
• Negative Sentiment: Within HC Wainwright’s note there was a small near‑term downgrade to Q2 2026 EPS (to -$0.36 from -$0.32), a mixed signal for the next quarter despite longer‑term upside revisions. Read More.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.